Research Analysts Offer Predictions for PLX Q1 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Protalix BioTherapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of $0.03 for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

Separately, StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday.

Protalix BioTherapeutics Trading Down 0.4 %

Shares of NYSE PLX opened at $2.42 on Tuesday. The stock has a market cap of $178.19 million, a P/E ratio of -18.62 and a beta of 0.75. The stock has a 50 day moving average of $1.98 and a two-hundred day moving average of $1.41. Protalix BioTherapeutics has a twelve month low of $0.82 and a twelve month high of $2.54.

Institutional Trading of Protalix BioTherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PLX. Sanctuary Advisors LLC acquired a new stake in shares of Protalix BioTherapeutics in the third quarter valued at about $38,000. Cubist Systematic Strategies LLC acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth approximately $37,000. Squarepoint Ops LLC grew its position in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after acquiring an additional 119,949 shares in the last quarter. GSA Capital Partners LLP boosted its position in Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after purchasing an additional 33,969 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Protalix BioTherapeutics during the 2nd quarter valued at approximately $67,000. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.